Cite

HARVARD Citation

    Klimek, V. et al. (n.d.). Phase 2 Study of Selinexor in Patients with Myelodysplastic Syndromes Refractory to Hypomethylating Agents: Interim Report. Leukemia research. pp. S32-. [Online]. 
  
Back to record